Line-1: Implications in the etiology of cancer, clinical applications, and pharmacologic targets

M. Khalid, P. Bojang, A. A.I. Hassanin, E. C. Bowers, E. M. Reyes-Reyes, Irma Ramos, Kenneth Ramos

Research output: Contribution to journalReview article

Abstract

Long interspersed nuclear elements-1 (Line-1 or L1) accounts for approximately 17% of the human genome. The majority of L1s are inactive, but ∼100 remain retrotransposon competent (RC-L1) and able to retrotranspose through RNA intermediates to different locations of the genome. L1 is involved in both disease initiation and progression via retrotransposition dependent and independent mechanisms. Retrotransposed L1 sequences disrupt genetic loci at sites of insertion, while the activities of L1 si/piRNAs, mRNAs, and ORF1 and ORF2 proteins, and have been implicated in the etiology and progression of several human diseases. Despite these relationships, little is known about the clinical utility of L1 as a biomarker of disease initiation and progression, or the utility of small molecules to inhibit and reverse the harmful effects of L1. In this review, we discuss the life cycle of L1, somatic and germline inhibitions, the mechanisms of L1 retrotransposition dependent and independent disease initiation and progression, clinical utilities, and potential of L1s as pharmacologic targets for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)51-60
Number of pages10
JournalMutation Research - Reviews in Mutation Research
Volume778
DOIs
StatePublished - Oct 1 2018

Fingerprint

Disease Progression
Neoplasms
Retroelements
Genetic Loci
Human Genome
Life Cycle Stages
Biomarkers
Genome
RNA
Messenger RNA
Proteins

Keywords

  • Biomarker
  • ceRNAs
  • EMT
  • Pharmacology
  • Retrotransposition

ASJC Scopus subject areas

  • Genetics
  • Health, Toxicology and Mutagenesis

Cite this

Line-1 : Implications in the etiology of cancer, clinical applications, and pharmacologic targets. / Khalid, M.; Bojang, P.; Hassanin, A. A.I.; Bowers, E. C.; Reyes-Reyes, E. M.; Ramos, Irma; Ramos, Kenneth.

In: Mutation Research - Reviews in Mutation Research, Vol. 778, 01.10.2018, p. 51-60.

Research output: Contribution to journalReview article

Khalid, M. ; Bojang, P. ; Hassanin, A. A.I. ; Bowers, E. C. ; Reyes-Reyes, E. M. ; Ramos, Irma ; Ramos, Kenneth. / Line-1 : Implications in the etiology of cancer, clinical applications, and pharmacologic targets. In: Mutation Research - Reviews in Mutation Research. 2018 ; Vol. 778. pp. 51-60.
@article{afc04a47adb04ec397b95547f264dc02,
title = "Line-1: Implications in the etiology of cancer, clinical applications, and pharmacologic targets",
abstract = "Long interspersed nuclear elements-1 (Line-1 or L1) accounts for approximately 17{\%} of the human genome. The majority of L1s are inactive, but ∼100 remain retrotransposon competent (RC-L1) and able to retrotranspose through RNA intermediates to different locations of the genome. L1 is involved in both disease initiation and progression via retrotransposition dependent and independent mechanisms. Retrotransposed L1 sequences disrupt genetic loci at sites of insertion, while the activities of L1 si/piRNAs, mRNAs, and ORF1 and ORF2 proteins, and have been implicated in the etiology and progression of several human diseases. Despite these relationships, little is known about the clinical utility of L1 as a biomarker of disease initiation and progression, or the utility of small molecules to inhibit and reverse the harmful effects of L1. In this review, we discuss the life cycle of L1, somatic and germline inhibitions, the mechanisms of L1 retrotransposition dependent and independent disease initiation and progression, clinical utilities, and potential of L1s as pharmacologic targets for the treatment of cancer.",
keywords = "Biomarker, ceRNAs, EMT, Pharmacology, Retrotransposition",
author = "M. Khalid and P. Bojang and Hassanin, {A. A.I.} and Bowers, {E. C.} and Reyes-Reyes, {E. M.} and Irma Ramos and Kenneth Ramos",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.mrrev.2018.09.003",
language = "English (US)",
volume = "778",
pages = "51--60",
journal = "Mutation Research - Reviews in Mutation Research",
issn = "1383-5742",
publisher = "Elsevier",

}

TY - JOUR

T1 - Line-1

T2 - Implications in the etiology of cancer, clinical applications, and pharmacologic targets

AU - Khalid, M.

AU - Bojang, P.

AU - Hassanin, A. A.I.

AU - Bowers, E. C.

AU - Reyes-Reyes, E. M.

AU - Ramos, Irma

AU - Ramos, Kenneth

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Long interspersed nuclear elements-1 (Line-1 or L1) accounts for approximately 17% of the human genome. The majority of L1s are inactive, but ∼100 remain retrotransposon competent (RC-L1) and able to retrotranspose through RNA intermediates to different locations of the genome. L1 is involved in both disease initiation and progression via retrotransposition dependent and independent mechanisms. Retrotransposed L1 sequences disrupt genetic loci at sites of insertion, while the activities of L1 si/piRNAs, mRNAs, and ORF1 and ORF2 proteins, and have been implicated in the etiology and progression of several human diseases. Despite these relationships, little is known about the clinical utility of L1 as a biomarker of disease initiation and progression, or the utility of small molecules to inhibit and reverse the harmful effects of L1. In this review, we discuss the life cycle of L1, somatic and germline inhibitions, the mechanisms of L1 retrotransposition dependent and independent disease initiation and progression, clinical utilities, and potential of L1s as pharmacologic targets for the treatment of cancer.

AB - Long interspersed nuclear elements-1 (Line-1 or L1) accounts for approximately 17% of the human genome. The majority of L1s are inactive, but ∼100 remain retrotransposon competent (RC-L1) and able to retrotranspose through RNA intermediates to different locations of the genome. L1 is involved in both disease initiation and progression via retrotransposition dependent and independent mechanisms. Retrotransposed L1 sequences disrupt genetic loci at sites of insertion, while the activities of L1 si/piRNAs, mRNAs, and ORF1 and ORF2 proteins, and have been implicated in the etiology and progression of several human diseases. Despite these relationships, little is known about the clinical utility of L1 as a biomarker of disease initiation and progression, or the utility of small molecules to inhibit and reverse the harmful effects of L1. In this review, we discuss the life cycle of L1, somatic and germline inhibitions, the mechanisms of L1 retrotransposition dependent and independent disease initiation and progression, clinical utilities, and potential of L1s as pharmacologic targets for the treatment of cancer.

KW - Biomarker

KW - ceRNAs

KW - EMT

KW - Pharmacology

KW - Retrotransposition

UR - http://www.scopus.com/inward/record.url?scp=85054802142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054802142&partnerID=8YFLogxK

U2 - 10.1016/j.mrrev.2018.09.003

DO - 10.1016/j.mrrev.2018.09.003

M3 - Review article

C2 - 30454683

AN - SCOPUS:85054802142

VL - 778

SP - 51

EP - 60

JO - Mutation Research - Reviews in Mutation Research

JF - Mutation Research - Reviews in Mutation Research

SN - 1383-5742

ER -